Active Ingredient History
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. Side effects include dizziness, drowsiness, weakness, nervousness, hallucinations, depression, vomiting, dry mouth, constipation, diarrhea, stomach pain, heartburn, increased muscle spasms, back pain, rash, sweating, and a tingling sensation in the arms, legs, hands, and feet. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Pain (Phase 2)
Brain Injuries, Traumatic (Phase 1)
Chronic Pain (Phase 2)
Healthy Volunteers (Phase 1)
Hernia, Inguinal (Phase 4)
Low Back Pain (Phase 4)
Melanoma (Phase 1)
Multiple Sclerosis (Phase 3)
Muscle Spasticity (Phase 4)
Opioid-Related Disorders (Phase 1)
Radiculopathy (Phase 3)
Sleep Disorders, Intrinsic (Phase 2)
Spinal Cord Injuries (Phase 3)
Stroke (Phase 3)
Substance-Related Disorders (Phase 1)
Thyroidectomy (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
